Technical Analysis for ALRN - Aileron Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 20 DMA Support | Bullish | -2.91% | |
| 200 DMA Support | Bullish | -2.91% | |
| Upper Bollinger Band Walk | Strength | -2.91% | |
| Above Upper BB | Strength | -2.91% | |
| Upper Bollinger Band Touch | Strength | -2.91% | |
| Stochastic Sell Signal | Bearish | 3.90% | |
| 20 DMA Support | Bullish | 3.90% |
| Alert | Time |
|---|---|
| Down 5% | about 21 hours ago |
| 60 Minute Opening Range Breakdown | about 22 hours ago |
| Down 3% | about 22 hours ago |
| Down 2 % | about 22 hours ago |
| Down 1% | about 24 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/04/2024
Aileron Therapeutics, Inc. Description
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Solid Tumors Tumor Inflammation Molecular Biology Lymphoma Cell Biology Metabolic Disease Oncogenes Peptides Hematological Malignancies Proteins P53 Tumor Suppressor Genes Treatment Of A Range Of Cancer Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.42 |
| 52 Week Low | 1.19 |
| Average Volume | 76,353 |
| 200-Day Moving Average | 3.83 |
| 50-Day Moving Average | 3.26 |
| 20-Day Moving Average | 3.69 |
| 10-Day Moving Average | 3.83 |
| Average True Range | 0.33 |
| RSI (14) | 60.47 |
| ADX | 18.38 |
| +DI | 21.55 |
| -DI | 12.45 |
| Chandelier Exit (Long, 3 ATRs) | 3.41 |
| Chandelier Exit (Short, 3 ATRs) | 4.20 |
| Upper Bollinger Bands | 4.13 |
| Lower Bollinger Band | 3.24 |
| Percent B (%b) | 0.85 |
| BandWidth | 24.28 |
| MACD Line | 0.20 |
| MACD Signal Line | 0.19 |
| MACD Histogram | 0.0162 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.44 | ||||
| Resistance 3 (R3) | 4.45 | 4.30 | 4.37 | ||
| Resistance 2 (R2) | 4.30 | 4.19 | 4.30 | 4.34 | |
| Resistance 1 (R1) | 4.15 | 4.12 | 4.08 | 4.15 | 4.32 |
| Pivot Point | 4.01 | 4.01 | 3.97 | 4.01 | 4.01 |
| Support 1 (S1) | 3.86 | 3.90 | 3.79 | 3.85 | 3.68 |
| Support 2 (S2) | 3.71 | 3.83 | 3.71 | 3.66 | |
| Support 3 (S3) | 3.56 | 3.71 | 3.63 | ||
| Support 4 (S4) | 3.56 |
